ANI Pharmaceuticals, Inc. (ANIP) Given Consensus Recommendation of “Hold” by Brokerages
Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have earned a consensus rating of “Hold” from the seven research firms that are covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $65.33.
A number of equities analysts recently weighed in on ANIP shares. Guggenheim restated a “buy” rating and set a $80.00 target price on shares of ANI Pharmaceuticals in a report on Tuesday, July 4th. ValuEngine downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Canaccord Genuity restated a “buy” rating and set a $60.00 target price on shares of ANI Pharmaceuticals in a report on Wednesday, August 9th. BidaskClub downgraded shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Finally, Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 5th.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Mesirow Financial Investment Management Inc. acquired a new position in ANI Pharmaceuticals during the second quarter worth $506,000. Dynamic Technology Lab Private Ltd bought a new position in ANI Pharmaceuticals during the second quarter worth $210,000. Raymond James Financial Services Advisors Inc. boosted its position in ANI Pharmaceuticals by 67.8% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 9,493 shares of the specialty pharmaceutical company’s stock worth $444,000 after purchasing an additional 3,837 shares during the period. Dana Investment Advisors Inc. boosted its position in ANI Pharmaceuticals by 0.8% during the second quarter. Dana Investment Advisors Inc. now owns 42,720 shares of the specialty pharmaceutical company’s stock worth $1,999,000 after purchasing an additional 341 shares during the period. Finally, Western Standard LLC bought a new position in ANI Pharmaceuticals during the second quarter worth $693,000. Institutional investors and hedge funds own 55.86% of the company’s stock.
Shares of ANI Pharmaceuticals (ANIP) opened at 50.09 on Friday. The company’s 50 day moving average is $46.71 and its 200 day moving average is $47.94. ANI Pharmaceuticals has a 12-month low of $42.23 and a 12-month high of $69.85. The company has a market capitalization of $582.95 million, a P/E ratio of 109.61 and a beta of 3.10.
ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.98 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.79 by $0.19. The business had revenue of $44.80 million for the quarter, compared to the consensus estimate of $43.20 million. ANI Pharmaceuticals had a net margin of 3.35% and a return on equity of 22.70%. The firm’s revenue for the quarter was up 43.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.11 earnings per share. Analysts expect that ANI Pharmaceuticals will post $3.84 earnings per share for the current fiscal year.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.